INS and Hypoglycemia: Short-acting insulin analogues (aspart, lispro and glulisine) were designed to mimic the fast physiological postprandial insulin release and long-acting insulin analogues (detemir and glargine) were designed to mimic the basal continuous insulin release with minimal peak action, thereby leading to a presumed decreased risk of hypoglycaemia.